BPC-157 Muscle Preservation Strategies: A Clinical Review

Does BPC-157 preserve muscle in humans?

The human evidence does not address it. A 2026 systematic review searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov to June 1, 2026 and found three human studies totaling 30 patients, all judged poor methodological quality, with certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [2]. FDA's own review identified five small human studies, which were meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot [1].

What the three human studies measured

• Knee pain chart review. One Florida clinic, 17 patients, 16 reached. Twelve received intra-articular BPC-157 alone and four received BPC-157 plus thymosin beta-4. Eleven of the 12 BPC-157-only patients (91.6%) reported significant improvement. There was no control group and no validated outcome tool; patients reported their results by phone, and most had received an injection 6 months to 1 year earlier. No adverse events were noted [8].
• Interstitial cystitis pilot. Twelve women aged 39 to 76 who had not responded to pentosan polysulfate received a total of 10 mg BPC-157 injected around the inflamed bladder wall in a single procedure. Ten of 12 reported complete symptom resolution and 2 of 12 about 80% improvement. Single arm, no placebo, patient-rated, no adverse events reported [9].
• Intravenous safety pilot. Two adults received 10 mg intravenously on day 1 and 20 mg on day 2. No measurable change appeared in the tested heart, liver, kidney, thyroid or glucose markers, and no side effects were reported. Two people cannot establish safety [10].

What the animal and cell data show

Blood flow to ischemic muscle. In a rat hind-limb ischemia model, BPC-157 sped recovery of blood flow measured by laser Doppler and increased the number of vessels seen on hind-limb muscle histology [3]. In the same experiments, BPC-157 raised vascular endothelial growth factor receptor 2 (VEGFR2) mRNA and protein in human vascular endothelial cells, but not VEGF-A, and activated a VEGFR2-Akt-eNOS signaling pathway [3]. That is a receptor-level angiogenesis finding in rats and cultured cells.

Soft-tissue healing. A 2019 review of BPC-157 in musculoskeletal soft tissue reported that published studies described positive healing effects across tendon, ligament and skeletal muscle injury models, but that most were small rodent studies and efficacy in humans was yet to be confirmed [4].

Tendon fibroblasts. A 2011 cell study found BPC-157 dose-dependently increased migration and spreading of rat tendon fibroblasts and phosphorylation of FAK and paxillin. These were tendon cells, not muscle fibers [11].

Mechanism is unresolved. FDA's July 2026 review states that BPC-157's molecular targets have not been identified, that its mechanisms 'remain poorly understood', and that dose-response relationships for the reported protective effects were not established. The reported protective effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1].

What doses have been used

There is no approved dose, because no FDA-approved product contains BPC-157 [1]. The doses in the small published human reports are a rectal enema of up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice for knee pain; 10 mg injected into the bladder wall once for interstitial cystitis; and 10 mg then 20 mg intravenously on two days in two healthy adults [1]. None of these is a recommended dose.

FDA found no human pharmacokinetic data for BPC-157 given subcutaneously, orally, nasally or on the skin [1]. After rectal enemas in two early studies BPC-157 was mostly undetectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [1].

Safety: what is known and what is not

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information. In the healthy-volunteer enema studies (meeting abstracts) the most frequent events were headache and flatulence [1].

FDA's search of its adverse-event database through December 4, 2025 turned up three reports, all injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused these [1].

Animal signals FDA noted: in 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised ALT, glucose and triglyceride levels. Longer studies and cancer-risk studies were not available [1].

FDA's stated concerns about compounded BPC-157 are that it may pose risk for immunogenicity for certain routes of administration and may have problems with peptide-related impurities and characterization of the active ingredient. The agency said it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [12].

Regulatory and legal status

BPC-157 is not an FDA-approved drug. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Its compounding status has shifted. BPC-157 sat in FDA's category 2 (bulk substances that may present significant safety risks) from September 2023 until April 22, 2026, when it moved to a 'nominated but withdrawn' table after the groups that nominated it withdrew. Removal was not a finding of safety, and the page still carries FDA's stated concerns [12][13]. BPC-157 appears in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), so the enforcement-discretion policy FDA applies to the first category does not cover it [5].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against the recommendation of FDA staff [14][1]. The vote is advice only; BPC-157 is not on the list, and listing requires formal rulemaking with a proposed rule, public comment and a final rule [14][13].

On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy covering six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [6][13]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [6][13]. For BPC-157 those conditions include the acetate form only; subcutaneous, intramuscular, oral or topical routes (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard; a patient-specific prescription; and MedWatch reporting of serious adverse events and quality problems [13].

The policy is not an approval and does not put BPC-157 on any list. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [6]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities (updated March 21, 2025) [15][13]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [15].

Sport

WADA names BPC-157 in class S0, non-approved substances, and it is prohibited at all times, in and out of competition [7]. It was first named as an example under S0 in the 2022 List and remains named in the 2026 List, in force since January 1, 2026, and in the 2027 List [16][17][7].